Woburn, Mass.-based BioProcessors Corp. has secured an $18 million Series C round of funding as it continues to commercialize its platform for managing biotech and pharmaceutical cell research environments.

Boston’s HLM Venture Partners led the round. The six-year-old startup’s existing investors Oxford Bioscience Partners, also of Boston, and Cambridge, Mass.-based HealthCare Ventures joined new investor New Science Ventures of New York in the round, which brings BioProcessors’ total raised to $42 million since its 2000 inception.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]